Amatuximab: Difference between revisions
Appearance
Content deleted Content added
removed Category:Experimental drugs; added Category:Experimental cancer drugs using HotCat |
Lncallahan (talk | contribs) m ADDED UNII |
||
Line 31: | Line 31: | ||
| ATC_suffix = |
| ATC_suffix = |
||
| PubChem = |
| PubChem = |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = 6HP0354G04 |
|||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = |
Revision as of 16:49, 21 April 2017
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | mesothelin |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6394H9870N1694O2024S46 |
Molar mass | 144.33 kg/mol (peptide) g·mol−1 |
(what is this?) (verify) |
Amatuximab is a chimeric monoclonal antibody designed for the treatment of cancer.[1]
Amatuximab was developed by Morphotek, Inc.
Amatuximab is also known as Anti-mesothelin monoclonal antibody MORAb-009. Amatuximab is an anti-mesothelin monoclonal antibody MORAb-009 binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing, and also called MORAb-009. [citation needed]
References
- Anti-mesothelin monoclonal antibody MORAb-009 entry in the public domain NCI Dictionary of Cancer Terms